Kura Oncology, Inc. (KURA)
12.65
-0.01
(-0.08%)
USD |
NASDAQ |
Aug 31, 16:00
12.64
-0.02
(-0.12%)
After-Hours: 20:00
Kura Oncology Cash from Operations (TTM) : -111.76M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -111.76M |
| March 31, 2026 | -77.98M |
| December 31, 2025 | -64.06M |
| September 30, 2025 | 87.80M |
| June 30, 2025 | 124.99M |
| March 31, 2025 | 111.23M |
| December 31, 2024 | 134.32M |
| September 30, 2024 | -169.12M |
| June 30, 2024 | -154.71M |
| March 31, 2024 | -137.80M |
| December 31, 2023 | -124.82M |
| September 30, 2023 | -117.05M |
| June 30, 2023 | -109.03M |
| March 31, 2023 | -113.75M |
| December 31, 2022 | -110.06M |
| September 30, 2022 | -106.90M |
| June 30, 2022 | -110.48M |
| March 31, 2022 | -108.22M |
| December 31, 2021 | -104.55M |
| September 30, 2021 | -99.49M |
| June 30, 2021 | -91.86M |
| March 31, 2021 | -78.52M |
| Date | Value |
|---|---|
| December 31, 2020 | -69.83M |
| September 30, 2020 | -65.46M |
| June 30, 2020 | -60.63M |
| March 31, 2020 | -60.33M |
| December 31, 2019 | -54.76M |
| September 30, 2019 | -51.04M |
| June 30, 2019 | -51.89M |
| March 31, 2019 | -50.06M |
| December 31, 2018 | -48.66M |
| September 30, 2018 | -45.92M |
| June 30, 2018 | -39.15M |
| March 31, 2018 | -32.67M |
| December 31, 2017 | -28.44M |
| September 30, 2017 | -27.70M |
| June 30, 2017 | -26.94M |
| March 31, 2017 | -26.66M |
| December 31, 2016 | -25.35M |
| September 30, 2016 | -24.22M |
| June 30, 2016 | -23.17M |
| March 31, 2016 | -21.12M |
| December 31, 2015 | -17.92M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Inovio Pharmaceuticals, Inc. | -80.58M |
| Fortress Biotech, Inc. | 120.36M |
| Syndax Pharmaceuticals, Inc. | -220.64M |
| Spero Therapeutics, Inc. | 19.58M |
| Gossamer Bio, Inc. | -164.59M |